Strategies for Liver Transplantation Tolerance

Area of Science:

• Immunology
• Transplantation Medicine
• Regenerative Medicine

Background:

• Liver transplant recipients require lifelong immunosuppression (IS) to prevent organ rejection.
• Chronic IS therapy carries significant risks, including infections, malignancies, and renal impairment.
• Current long-term outcomes for liver transplants have stagnated despite therapeutic advancements.

Purpose of the Study:

• To review protocols for active tolerance induction in liver transplantation.
• To identify tolerogenic cell populations and barriers to achieving tolerance.
• To propose novel IS agents and strategies to promote immunomodulatory mechanisms favoring tolerance.

Main Methods:

• Review of existing literature on liver transplantation and immunosuppression.
• Analysis of pilot clinical trials employing regulatory T-cell (Treg) based immunomodulation.
• Identification of key tolerogenic cell populations and associated barriers.
• Proposal of novel immunosuppressive agents and immunomodulatory mechanisms.

Main Results:

• A pilot trial demonstrated that peri-transplant immunomodulation with Tregs can reduce donor-specific alloreactivity.
• Early IS withdrawal was achieved in a pilot study using Treg-based approaches.
• Active tolerance induction protocols are being developed to overcome barriers to IS withdrawal.

Conclusions:

• Active tolerance induction strategies, particularly those involving Tregs, show promise for early immunosuppression withdrawal in liver transplantation.
• Novel IS agents and improved monitoring are crucial for establishing widespread active tolerance induction protocols.
• Further research is needed to optimize these strategies and improve long-term liver transplant outcomes by reducing IS burden.